| “The appointment is made for an interim period to ensure a smooth transition to the new CFO, for which the identification and appointment process is in progress,” the company stated in regulatory filing.
Arun Kumar Sharma is a strategic and result-driven financial leader with over three decades of progressive experience across corporate finance, global treasury, investor relations, risk management, financial restructuring, insurance, capex control, and business transformation.
He has held various positions in Jubilant Bhartia Group including CFO role in Jubilant Pharma Holdings Inc. USA for approximately 4 years, Jubilant Lifesciences (Chemical Business) for approximately 3 years and Jubilant Pharmova for around 2 years (April’ 2021-May’2023).
Jubilant Pharmova is a globally present company engaged in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, contract research, development and manufacturing (CRDMO), generics, and proprietary novel drugs businesses.
The company's consolidated net profit declined 78.66% to Rs 102.90 crore despite a 9.21% rise in revenue to Rs 1,878.90 crore in Q1 FY26 over Q1 FY25.
The counter was down 0.65% to currently trade at Rs 1084.95 on the BSE. |